Double-Blind, Randomized Control Trial To Evaluate the Efficacy of Duct Tape Versus Placebo for the Treatment of Verruca Vulgaris
18 Years
N/A
Both
Wart, Common Wart, Verruca Vulgaris, Verruca Plantaris, Plantar Wart
Trial Information
Double-Blind, Randomized Control Trial To Evaluate the Efficacy of Duct Tape Versus Placebo for the Treatment of Verruca Vulgaris
ABSTRACT (233 word count)
Objective: To evaluate the efficacy of duct tape occlusion therapy for the treatment of
common warts.
Design: A double-blinded, controlled, clinical intervention trial. Setting: Veterans Affairs
Medical Center. Participants: A total of 90 immunocompetent adult volunteers with at least
one wart measuring between 2-15 mm were enrolled in this study between October 2004 and July
2005; 80 patients completed the study.
Intervention: Patients were randomized using a computer-generated code to receive either
pads consisting of moleskin with transparent duct tape (active) or moleskin alone (control).
Patients were instructed to wear the pads for 7 consecutive days and leave the pad off on
the 7th evening. This process was repeated for 2 months or until the wart resolved,
whichever occurred first. Follow-up visits occurred at 1 and 2 months.
Main Outcome Measure: 100% resolution of the wart. Secondary outcomes included change in
size of the target wart and recurrence rates at 6 months for warts with complete resolution.
Results: There were no statistically significant differences in the proportions of patients
with resolution of the target wart (duct tape=8/39, 21% vs. control=9/41, 22%). Of patients
with complete resolution, 75% (6/8) in the duct tape group and 33% (3/9) of those in the
control group had recurrence of the target wart by the sixth month.
Conclusions: Occlusive therapy with transparent duct tape is not significantly better than
moleskin alone for treatment of common warts in adults.
Inclusion Criteria:
1) ability to comprehend and provide informed consent; 2) age greaterthan 18 years old; and 3) at least one common wart, measuring 2-15 millimeters in
diameter.
Exclusion Criteria: 1) pregnant or lactating females; 2) treatment of the target wart
within the past four weeks by any modality; 3) immunodeficiency state (cancer
chemotherapy, systemic steroids, genetic immunodeficiency, transplant status, etc.); 4)
genital wart only; 5) a history of hypersensitivity or allergy to adhesive tape; 6)
documented allergy to latex; and/or 7) participation in another interventional study or
use of any investigational drug within 30 days prior to enrollment.
-
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Outcome Measure:
100% resolution of target wart
Principal Investigator
Erin M. Warshaw, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Minneapolis Veterans Affairs Medical Center
Authority:
United States: Federal Government
Study ID:
3482-A
NCT ID:
NCT00328991
Start Date:
October 2004
Completion Date:
December 2005
Related Keywords:
- Wart
- Common Wart
- Verruca Vulgaris
- Verruca Plantaris
- Plantar Wart
- wart
- common wart
- verruca vulgaris
- verruca plantaris
- plantar wart
- duct tape
- occlusion therapy
- Warts
- Foot Diseases
Name | Location |
|---|---|
| Minneapolis Veterans Affairs Medical Center | Minneapolis, Minnesota 55417 |
